Ignite Creation Date:
2024-05-06 @ 1:34 PM
Last Modification Date:
2024-10-26 @ 1:16 PM
Study NCT ID:
NCT04069819
Status:
COMPLETED
Last Update Posted:
2022-10-12
First Post:
2019-08-25
Brief Title:
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
Double-blind Randomized Placebo-Controlled Pilot Study of the Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cilostazol is a PDE 3 inhibitor which showed as decrease in HAM-D scores in post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and through promotion of neurogenesis These beneficial effects on post-stroke depression may be involved in activation of CREBBDNF signalingThe aim of the current study is to evaluate the potential adjunct antidepressant effect of cilostazol in adult patients with MDD Furthermore we will assess the relationship between HAM-D score and BDNF as well as their role as a therapeutic targets of MDD
Detailed Description:
Cilostazol produces various powerful pleiotropic effects via restoration of intracellular second messenger cyclic adenosine monophosphate cAMP Treatment with cilostazol against cerebral ischemic injury ameliorates negative effects of cerebral hypoperfusion through the PDE3- cAMP signaling cascade with subsequent activation of inducible transcription factor cAMP response element-binding protein CREB suggesting the importance of the CREB signaling pathway
Activation of CREB promotes the gene expression of neuroprotective molecules that activate subsequent anti-apoptotic pathways with the gene expression of brain-derived neurotrophic factor BDNF BDNF also regulates neurogenesis proliferation and survival of neural stem or progenitor cells as well as neuronal survival In addition CREB and BDNF signaling play an important role in the pathophysiology of major depressive disorder
Psychopharmacotherapy with antidepressants or mood stabilizers provides an effective treatment for depression after stroke but alternative therapy by activation of CREB and BDNF signaling may exert beneficial effects on various aspects of negative mood Drugs that activate CREB and BDNF signaling may provide a potential therapeutic approach for treatment of poststroke depression via neural cell survival and proliferation of neural progenitor cells
The aim of the current study is to evaluate the potential adjunct antidepressant effect of cilostazol in adult patients with MDD Furthermore we will assess the relationship between HAM-D score and BDNF as well as their role as a therapeutic targets of MDD
Activation of CREB promotes the gene expression of neuroprotective molecules that activate subsequent anti-apoptotic pathways with the gene expression of brain-derived neurotrophic factor BDNF BDNF also regulates neurogenesis proliferation and survival of neural stem or progenitor cells as well as neuronal survival In addition CREB and BDNF signaling play an important role in the pathophysiology of major depressive disorder
Psychopharmacotherapy with antidepressants or mood stabilizers provides an effective treatment for depression after stroke but alternative therapy by activation of CREB and BDNF signaling may exert beneficial effects on various aspects of negative mood Drugs that activate CREB and BDNF signaling may provide a potential therapeutic approach for treatment of poststroke depression via neural cell survival and proliferation of neural progenitor cells
The aim of the current study is to evaluate the potential adjunct antidepressant effect of cilostazol in adult patients with MDD Furthermore we will assess the relationship between HAM-D score and BDNF as well as their role as a therapeutic targets of MDD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None